Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Janux Therapeutics, Inc. (JANX : NSDQ)

• Company Description    Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $28.71 Daily Weekly Monthly 20 Day Moving Average: 1,189,707 shares Shares Outstanding: 60.09 (millions) Market Capitalization: $1,725.30 (millions) Beta: 2.83 52 Week High: $71.71 52 Week Low: $21.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.62% 17.45% 12 Week 25.76% 17.47% Year To Date -46.38% -53.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10955 Vista Sorrento Parkway Suite 200 - San Diego,CA 92130 USA ph: 858-751-4493 fax: - investors@januxrx.com http://www.januxrx.com

• General Corporate Information    Officers David Campbell - President and Chief Executive Officer Ron Barrett - Chairperson of the Board of Directors Vickie Capps - Director Eric Dobmeier - Director Sheila Gujrathi - Director Peer Information Janux Therapeutics, Inc. (CORR.) Janux Therapeutics, Inc. (RSPI) Janux Therapeutics, Inc. (CGXP) Janux Therapeutics, Inc. (BGEN) Janux Therapeutics, Inc. (GTBP) Janux Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 47103J105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 60.09 Most Recent Split Date: (:1) Beta: 2.83 Market Capitalization: $1,725.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.72 Price/Cash Flow: - Price / Sales: 132.22 EPS Growth vs. Year Ago Period: -400.00% vs. Previous Quarter: -44.74% Sales Growth vs. Year Ago Period: -82.56% vs. Previous Quarter: -95.07% ROE 09/30/25 - - 06/30/25 - -11.48 03/31/25 - -9.29 ROA 09/30/25 - - 06/30/25 - -11.01 03/31/25 - -8.89 Current Ratio 09/30/25 - - 06/30/25 - 47.03 03/31/25 - 58.47 Quick Ratio 09/30/25 - - 06/30/25 - 47.03 03/31/25 - 58.47 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -24,064.01 03/31/25 - -832.71 Book Value 09/30/25 - - 06/30/25 - 16.74 03/31/25 - 17.11 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©